CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced that its Safety Monitoring Committee has recommended proceeding with dose escalation to the fifth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE